Glenmark Pharmaceuticals Ltd
Glenmark Pharma. | 532296
Stock Performance
Ratios
About Company
- Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977
- The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity)
- It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets
- The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India
- The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology
- Its branded generics business has a significant presence in markets across emerging economies including India
- The company has 11 manufacturing facilities across US, India, Argentina, Czech Republic and Switzerland
- The generics business services the requirements of developed markets like the US and Western Europe
- The API business sells products in over 80 countries including the US, various countries in the EU, South America and India
- In the year 1979, the company entered dermatology market with the launch of 'Candid Cream'
Technical Indicators
Pivot Points
Volume Analysis
Growth Rate
All figures in ₹ Crores
No Information Available
No shareholding data available at this time.
News
No Information Available
Peers
#IndiaInvests
Trusted by 2.5 lac + Indians for their wealth-building needs
Invest in stocks with ease
Open your account in less than 10 mins*
By proceeding, you agree to all T&C *
Frequently Asked Questions
What is Share Price of Glenmark Pharmaceuticals Ltd?
The current share price of Glenmark Pharmaceuticals Ltd (Glenmark Pharma.) is ₹2110.70. This price reflects the latest market valuation and is updated in real-time during trading hours.
What is the P/E Ratio of Glenmark Pharmaceuticals Ltd?
The Price-to-Earnings (P/E) ratio of Glenmark Pharmaceuticals Ltd is 2110.70. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.
What is the 52-week high and low of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd has a 52-week high of ₹2284.80 and a 52-week low of ₹1275.50. This range shows the stock's price volatility over the past year.
What is the Dividend Yield of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd offers a dividend yield of 0.12%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.
What is the EPS of Glenmark Pharmaceuticals Ltd?
The Earnings Per Share (EPS) of Glenmark Pharmaceuticals Ltd is ₹89.11. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.
What is the ROE of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd has a Return on Equity (ROE) of 6.78%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.
Disclaimer:
Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.
